Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Self-citationAustin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Self-citationHoussiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Self-citationBoumpas, D. T., Austin, H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00003 · Cited by 500
Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., & Li, F.-K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080686 · Cited by 479
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20666 · Cited by 391
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Self-citationIllei, G. G., Takada, K., Parkin, D., Austin, H. A., Crane, M., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Pando, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10142 · Cited by 329
McCune, W. J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R., & Fox, D. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806023182203 · Cited by 282
Fernández, M., Alarcón, G. S., Calvo‐alén, J., Andrade, R., McGwin, G., Vilá, L. M., Reveille, J. D., & LUMINA Study Group (2007) · Arthritis Care & Research · doi:10.1002/art.22672 · Cited by 272
Robson, R. A., Cecka, J. M., Opelz, G., Budde, M., & Sacks, S. T. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01125.x · Cited by 266
ONG, L. M., HOOI, L. S., LIM, T. O., GOH, B. L., AHMAD, G., GHAZALLI, R., TEO, S. M., WONG, H. S., TAN, S. Y., SHAARIAH, W., et al. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00444.x · Cited by 252
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
Ioannidis, J. P. A., Boki, K. A., Katsorida, M. E., Drosos, A. A., Skopouli, F. N., Boletis, J. N., & Moutsopoulos, H. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00832.x · Cited by 231
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
Barr, R. G. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg345 · Cited by 206
Outcomes in African Americans and Hispanics with lupus nephritis
Contreras, G., Lenz, O., Pardo, V., Borja, E., Cely, C., Iqbal, K., Nahar, N., de La Cuesta, C., Hurtado, A., Fornoni, A., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000243 · Cited by 202
Self-citationAdler, M., Chambers, S., Edwards, C., Neild, G., & Isenberg, D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel039 · Cited by 163
Self-citationMoore, R., & Derry, S. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2093 · Cited by 147
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis
Walsh, M. W., James, M. T., Jayne, D. R. W., Tonelli, M. A., Manns, B., & Hemmelgarn, B. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01200307 · Cited by 139
Self-citationSinclair, A., Appel, G. B., Dooley, M. A., Ginzler, E. M., Isenberg, D. A., Jayne, D. R. W., Wofsy, D., & Solomons, N. (2007) · Lupus · doi:10.1177/0961203307084712 · Cited by 121
Self-citationUpdate on the treatment of lupus nephritis
Waldman, M. A., & Appel, G. B. (2006) · Kidney International · doi:10.1038/sj.ki.5001777 · Cited by 112
Self-citationCardiovascular risk factors and the long-term outcome of lupus nephritis
Font, J. A., Ramos-Casals, M., Cervera, R., García-Carrasco, M., Torras, A., Sisó, A., Darnell, A., & Ingelmo, M. (2001) · QJM · doi:10.1093/qjmed/94.1.19 · Cited by 94
Newer Drugs for the Treatment of Lupus Nephritis
Kuiper-Geertsma, D. G., & Derksen, R. H. W. M. (2003) · Drugs · doi:10.2165/00003495-200363020-00004 · Cited by 43
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Self-citation
Metadata
- Authors
- Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., & Wofsy, D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-05
- Volume
- 20
- Issue
- 5
- Pages
- 1103-1112
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2171121999
- Cited by
- 1,118
- References
- 29
- FWCI
- 50.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.